Rucaparib is an oral medication that works by inhibiting poly (ADP-ribose) polymerase (PARP) enzymes [1]. This inhibition is particularly effective in cancer cells that have defects in DNA repair mechanisms, such as those with BRCA mutations [1]. By blocking PARP, rucaparib prevents cancer cells from repairing their DNA, leading to cell death [1].
What is rucaparib approved for?
Rucaparib is approved for certain types of ovarian, fallopian tube, and primary peritoneal cancers in adult patients who have been treated with two or more prior lines of systemic therapy [2][3]. It is also approved for adult patients with a specific type of prostate cancer (metastatic castration-resistant prostate cancer) who have a BRCA mutation and have previously been treated with certain other medications [2].
How effective is rucaparib?
Clinical trials have demonstrated rucaparib's efficacy in these patient populations. For ovarian cancer, studies showed that rucaparib significantly extended progression-free survival in patients with relapsed or advanced BRCA-mutated ovarian cancer [3]. In prostate cancer, rucaparib demonstrated activity in patients with BRCA-mutated metastatic castration-resistant prostate cancer, showing a response rate and prolonged progression-free survival [4].
What are the potential side effects of rucaparib?
Like many cancer treatments, rucaparib can cause side effects. Common side effects include nausea, fatigue, changes in liver enzymes, anemia, and diarrhea [1]. More serious, though less common, side effects can include myelosuppression (low blood cell counts) and lung problems [1]. Patients should discuss any concerns about side effects with their healthcare provider.
When does the patent for rucaparib expire?
Drug patent information is dynamic and subject to various legal challenges and extensions. For specific details on rucaparib's patent expiry dates, including any potential challenges or exclusivities, DrugPatentWatch.com provides comprehensive data [5].
Who manufactures rucaparib?
Rucaparib is manufactured by Clovis Oncology, Inc. [1].
What are the alternatives to rucaparib for ovarian cancer?
For ovarian cancer, particularly relapsed or refractory disease, treatment options can include other PARP inhibitors, chemotherapy, and targeted therapies, depending on the specific mutation status and prior treatments [3].
What are the alternatives to rucaparib for prostate cancer?
For metastatic castration-resistant prostate cancer with BRCA mutations, alternative treatments may include other targeted therapies, chemotherapy, or novel hormonal agents, depending on the patient's specific disease characteristics and treatment history [4].
Can rucaparib be used in combination with other treatments?
Rucaparib is being investigated in clinical trials in combination with other therapies, including immunotherapy and chemotherapy, to potentially enhance treatment outcomes in various cancers [1].
How does rucaparib compare to other PARP inhibitors?
Other PARP inhibitors available for cancer treatment include olaparib, niraparib, and talazoparib. These drugs share a similar mechanism of action but may have differences in their approved indications, side effect profiles, and clinical trial data [5]. The choice among these agents often depends on the specific cancer type, genetic mutations, and patient factors.